Zydus plans to launch its diabetes and obesity injection using a reusable adjustable pen device after patent expiry, as more Indian drugmakers enter the market.

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, ...

Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on Wednesday.

With multiple launches lined up for March, companies are betting on device innovation, brand strategy, and patient-support ...

Abbott has partnered with Novo Nordisk to commercialise Extensior, a competitively priced second brand of semaglutide-based Ozempic in India, aiming to widen access to diabetes treatment ...

Under the agreement between the companies, Abbott will commercialize Novo Nordisk's semaglutide (Ozempic) under the brand ...

One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system ...

Zydus plans to launch innovative semaglutide injection in India on day 1 of patent expiry: Our Bureau, Mumbai Thursday, February 26, 2026, 11:30 Hrs [IST] Zydus Lifesciences Limit ...

Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after.